Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Pedro-Antonio Regidor"'
Publikováno v:
Women's Health, Vol 19 (2023)
The spironolactone derivative drospirenone is combined with ethinylestradiol or estetrol in combined oral contraceptives. Formulations with 17-β-estradiol are used to treat climacteric symptoms. A drospirenone-only formulation has been introduced fo
Externí odkaz:
https://doaj.org/article/5780cc6571144a9d9812417d75cf3b02
Publikováno v:
BMC Women's Health, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background A new estrogen-free contraceptive has been approved by both the FDA and more than 15 European authorities. It is composed of drospirenone (DRSP) at a dosage of 4 mg in a regimen 24/4. The molecule is known to have anti-gonadotropi
Externí odkaz:
https://doaj.org/article/52e18a8935a64a1990c1d3d02be0e5ae
Publikováno v:
Women's Health, Vol 17 (2021)
Cervical cancer, the third most common cancer in women, is caused in nearly all cases by a persistent infection with high-risk types of the human papillomavirus. Although human papillomavirus infections are 80%–90% transient and disappear spontaneo
Externí odkaz:
https://doaj.org/article/c8f1cdb5eee24d2685e719ca2f53cc7a
Publikováno v:
Women's Health, Vol 16 (2020)
Objective: The primary objective of this trial was to assess the transfer of drospirenone to breast milk after daily administration of an oral test preparation containing 4 mg of drospirenone at the steady state. The secondary objective of the trial
Externí odkaz:
https://doaj.org/article/018d945ebdbf4ff0ace20e39c46819dd
Autor:
Pedro-Antonio Regidor, Xavier de la Rosa, Anna Müller, Manuela Mayr, Fernando Gonzalez Santos, Rafael Gracia Banzo, Jose Miguel Rizo
Publikováno v:
Biomedicines, Vol 10, Iss 2, p 456 (2022)
Introduction: Polycystic ovary syndrome (PCOS) is an endocrinological disorder that affects 5–15% of women of their reproductive age and is a frequent cause of infertility. Major symptoms include hyperandrogenism, ovulatory dysfunction, and often o
Externí odkaz:
https://doaj.org/article/ba9cf3a0e1a84c3f846d6803e3e89090
Autor:
Pedro-Antonio Regidor, Marta Kaczmarczyk, Esther Schiweck, Maren Goeckenjan-Festag, Henry Alexander
Publikováno v:
Gynecological Endocrinology, Vol 34, Iss 3, Pp 256-260 (2018)
AbstractFertility awareness-based (FAB) methods represent a term that includes all family planning methods that are based on the identification of the fertile window. They are based on the woman’s observation of physiological signs of the fertile a
Externí odkaz:
https://doaj.org/article/100bae3fb7f54ee38d1bd10b6da4c962
Autor:
Pedro-Antonio Regidor, Anna Mueller, Manuela Sailer, Fernando Gonzalez Santos, Jose Miguel Rizo, Fernando Moreno Egea
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 1, p 384 (2020)
PCOS as the most common endocrine disorder of women in their reproductive age affects between 5–15% of the female population. Apart from its cardinal symptoms, like irregular and anovulatory cycles, hyperandrogenemia and a typical ultrasound featur
Externí odkaz:
https://doaj.org/article/0669689a6d3445d3815825ebedb226ea
Autor:
Bernd Lesoine, Pedro-Antonio Regidor
Publikováno v:
International Journal of Endocrinology, Vol 2016 (2016)
Polycystic ovarian syndrome (PCOS) is one of the pathological factors involved in the failure of in vitro fertilization (IvF). The aim of the present study was to investigate if the combination of myoinositol + folic acid was able to improve the oocy
Externí odkaz:
https://doaj.org/article/4b4f2bcdbbac4e4d9f29310e3246d20b
Publikováno v:
International Journal of Endocrinology, Vol 2016 (2016)
The use of 2×2000 mg myoinositol + 2×200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study
Externí odkaz:
https://doaj.org/article/e722859319ee4d1a9d6a724f86898f71
Autor:
Ali Kubba, Kristina Gemzell-Danielsson, Santiago Palacios, Inka Wiegratz, Giovanni Grandi, Enrico Colli, Pedro Antonio Regidor
Publikováno v:
The European Journal of Contraception & Reproductive Health Care. 28:36-43